BRIGHTEN OPTIX, Taiwan’s largest manufacturer of rigid contact lenses, announced on the 4th that it has officially signed a share swap agreement with Carl Zeiss Vision International GmbH, a wholly owned subsidiary of the global optics and optoelectronics leader Carl Zeiss AG. Following the transaction, BRIGHTEN OPTIX will become a 100% wholly owned subsidiary of ZEISS.
The transaction is expected to be completed, including delisting procedures, by the first quarter of 2026. BRIGHTEN OPTIX emphasized its commitment to safeguarding shareholder interests by strictly adhering to the information disclosure requirements of the Securities and Exchange Act and the Business Mergers and Acquisitions Act, ensuring full transparency. Investors are advised to stay informed.
According to BRIGHTEN OPTIX, the deal is built on the highly complementary product portfolios, technological strengths, and long-term strategic synergy between the two companies. ZEISS, with a history spanning over 180 years, is globally renowned for its deep technological foundation and brand credibility. Meanwhile, BRIGHTEN OPTIX has long specialized in orthokeratology and other advanced vision correction solutions, holding a leading position in the Asian market with internationally recognized R&D capabilities. This integration marks a joint effort to expand innovation, elevate manufacturing quality, and strengthen global market influence.
BRIGHTEN OPTIX highlighted the strong complementarity between the two companies’ product lines. Rather than causing resource redundancy, the merger is expected to unlock substantial synergy, further accelerating international expansion.
Upon completion of the transaction, the original management team will remain in place. The company’s operations and organizational structure will remain unchanged. Current General Manager Richard Wu will continue to lead the technical and R&D teams, ensuring the ongoing execution of core projects and the seamless continuation of innovation and knowledge transfer.
Richard Wu stated, “Since my father founded BRIGHTEN OPTIX, our team has spent 50 years advancing in this field. The development of orthokeratology lenses represents a significant milestone for Taiwan in the optical healthcare industry. Joining the ZEISS Group now offers us the opportunity to bring our products and technology to a larger global stage. This is not only a new milestone, but also a recognition of Taiwan’s optical capabilities.”
Sven Hermann, CEO of ZEISS Vision Care and member of the Executive Board, said he was honored to partner with BRIGHTEN OPTIX. He noted that this collaboration will enrich ZEISS’s myopia management product portfolio and help provide better protection for children whose daily lives are affected by myopia. He described the acquisition as a critical step in ZEISS’s mission to offer lifelong visual health solutions to customers worldwide.
BRIGHTEN OPTIX is also widely recognized for its commitment to R&D and outstanding achievements in the field, making it an ideal partner for ZEISS. With ZEISS’s legacy of technical excellence and evidence-based innovation, both parties are confident that their combined strengths will become a significant advantage in their collaboration.
BRIGHTEN OPTIX stressed that it will continue to base its R&D operations in Taiwan while leveraging ZEISS’s international resources and brand power. The company aims to enhance its visibility and momentum in the Asian market and create long-term value for customers, employees, and partners alike.
Resource: 亨泰光與德國蔡司簽股份轉換契約 成蔡司100%子公司
